The combination treatment of MWA and Flt3L has been observed to induce the differentiation of TdLN‐TTSM cells, which were verified as bona fide responders to PD‐1/PD‐L1 blockade therapy.[59] Therefore, this synergistic treatment regime holds the potential to augment the antitumor effects of PD‐1 blockade in lung cancer. This evidence concerns the gene FLT3LG and lung carcinoma.